I-Mab Secures $65M to Accelerate Givastomig's Breakthrough in Precision Immuno-Oncology

I-Mab, a U.S.-based global biotech company (NASDAQ: IMAB) at the forefront of precision immuno-oncology, is thrilled to announce a successful funding round in which it raised $65,000,000. This significant investment underscores the confidence that investors have in I-Mab’s groundbreaking mission and its innovative pipeline, which is dedicated to improving the treatment of cancer. At the heart of I-Mab’s portfolio is givastomig, a next-generation bispecific antibody engineered for Claudin 18.2-positive gastric cancers. This best-in-class candidate is designed to conditionally activate T cells through the 4-1BB signaling pathway specifically within the tumor microenvironment, ensuring potent anti-tumor activity while minimizing the toxicities that have historically limited similar therapies. In Phase 1 trials, givastomig demonstrated strong tumor-binding characteristics and promising synergistic effects, paving the way towards its development as a first-line therapeutic option for metastatic gastric cancers, with the potential to benefit patients suffering from other solid tumors as well. The funds raised will be instrumental in accelerating the further development of givastomig along with other promising candidates in I-Mab’s pipeline. Part of the investment will be allocated to advancing clinical trials and expanding research efforts to optimize treatment protocols, maximize efficacy, and further elucidate the drug’s mechanism of action. Additionally, the funding provides a robust platform to support upcoming initiatives, including the anticipated Mini Oral presentation at the European Society of Medical Oncology Gastrointestinal Cancers Congress 2025 in Barcelona, Spain. This pivotal event will showcase new data on givastomig, reinforcing I-Mab’s commitment to transforming immuno-oncology research and ultimately, the future of cancer therapy.